Mark Eisner M.D., M.P.H.
Net Worth
Last updated:
What is Mark Eisner M.D., M.P.H. net worth?
The estimated net worth of Dr. Mark Eisner M.D., M.P.H. is at least $3,498,096 as of 7 Jun 2023. He owns shares worth $1,775,196 as insider, has earned $614,320 from insider trading and has received compensation worth at least $1,108,580 in FibroGen, Inc..
What is the salary of Mark Eisner M.D., M.P.H.?
Dr. Mark Eisner M.D., M.P.H. salary is $554,290 per year as Chief Medical Officer in FibroGen, Inc..
How old is Mark Eisner M.D., M.P.H.?
Dr. Mark Eisner M.D., M.P.H. is 59 years old, born in 1966.
What stocks does Mark Eisner M.D., M.P.H. currently own?
As insider, Dr. Mark Eisner M.D., M.P.H. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| FibroGen, Inc. (FGEN) | Chief Medical Officer | 162,862 | $10.9 | $1,775,196 |
What does FibroGen, Inc. do?
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Mark Eisner M.D., M.P.H. insider trading
FibroGen, Inc.
Dr. Mark Eisner M.D., M.P.H. has made 7 insider trades in 2023, according to the Form 4 filled with the SEC. Most recently he sold 2,042 units of FGEN stock worth $34,792 on 7 Jun 2023.
The largest trade he's ever made was exercising 9,182 units of FGEN stock on 4 Apr 2023. As of 7 Jun 2023 he still owns at least 162,862 units of FGEN stock.
FibroGen key executives
FibroGen, Inc. executives and other stock owners filed with the SEC:
- Dr. Elias Kouchakji (69) Senior Vice President of Clinical Devel., Drug Safety & Pharmacovigilance
- Dr. Mark Eisner M.D., M.P.H. (59) Chief Medical Officer
- Mr. Enrique A. Conterno (58) Chief Executive Officer & Director
- Mr. James A. Schoeneck (67) Chairman
- Mr. Pat Cotroneo (61) Executive Advisor to Chief Executive Officer
- Mr. Thane Wettig (60) Chief Commercial Officer